Certuity LLC Has $424,000 Holdings in Align Technology, Inc. (NASDAQ:ALGN)

Certuity LLC boosted its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 19.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,547 shares of the medical equipment provider’s stock after purchasing an additional 249 shares during the period. Certuity LLC’s holdings in Align Technology were worth $424,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Commonwealth Equity Services LLC boosted its holdings in shares of Align Technology by 9.4% during the third quarter. Commonwealth Equity Services LLC now owns 5,046 shares of the medical equipment provider’s stock worth $1,541,000 after purchasing an additional 435 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Align Technology by 4.3% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 12,008 shares of the medical equipment provider’s stock valued at $3,666,000 after buying an additional 500 shares during the period. Robeco Institutional Asset Management B.V. grew its holdings in shares of Align Technology by 202.1% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 71,902 shares of the medical equipment provider’s stock valued at $21,953,000 after acquiring an additional 48,098 shares in the last quarter. Xponance Inc. increased its stake in shares of Align Technology by 0.5% in the third quarter. Xponance Inc. now owns 20,943 shares of the medical equipment provider’s stock worth $6,394,000 after acquiring an additional 107 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its holdings in shares of Align Technology by 26.0% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 21,040 shares of the medical equipment provider’s stock worth $6,424,000 after acquiring an additional 4,346 shares in the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Align Technology Stock Performance

NASDAQ ALGN opened at $284.52 on Thursday. The stock has a market capitalization of $21.41 billion, a PE ratio of 46.87, a P/E/G ratio of 5.65 and a beta of 1.65. The stock has a 50-day simple moving average of $312.28 and a 200 day simple moving average of $271.29. Align Technology, Inc. has a twelve month low of $176.34 and a twelve month high of $413.20.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.13. The company had revenue of $956.73 million during the quarter, compared to analyst estimates of $928.57 million. Align Technology had a return on equity of 14.15% and a net margin of 11.80%. As a group, equities research analysts forecast that Align Technology, Inc. will post 7.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Align Technology news, EVP Emory Wright sold 2,524 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $287.45, for a total value of $725,523.80. Following the sale, the executive vice president now directly owns 709 shares in the company, valued at approximately $203,802.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Align Technology news, EVP Emory Wright sold 2,524 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total value of $725,523.80. Following the completion of the sale, the executive vice president now owns 709 shares in the company, valued at approximately $203,802.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph Lacob sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total value of $4,548,300.00. Following the sale, the director now owns 131,994 shares in the company, valued at $40,023,220.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,524 shares of company stock valued at $8,403,924. 0.62% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have weighed in on ALGN shares. Piper Sandler reaffirmed an “overweight” rating and issued a $375.00 target price (up from $355.00) on shares of Align Technology in a research report on Thursday, April 25th. Stifel Nicolaus increased their price target on shares of Align Technology from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. SVB Leerink began coverage on shares of Align Technology in a report on Monday, February 26th. They issued a “market perform” rating and a $310.00 price objective for the company. UBS Group raised their target price on Align Technology from $280.00 to $320.00 and gave the company a “neutral” rating in a report on Monday, April 15th. Finally, Robert W. Baird increased their price objective on Align Technology from $333.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $353.00.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.